Active thrombopoiesis is associated with worse severity and activity of chronic GVHD

[1]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[2]  K. Calvo,et al.  Measurement of the absolute immature platelet number reflects marrow production and is not impacted by platelet transfusion , 2012, Transfusion.

[3]  J. Miguel,et al.  Evaluation of prognostic factors among patients with chronic graft-versus-host disease , 2012, Haematologica.

[4]  A. Böhm,et al.  Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study , 2012, Leukemia.

[5]  S. Steinberg,et al.  Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity , 2011, Leukemia.

[6]  Y. Matsuno,et al.  Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation. , 2010, Blood.

[7]  D. Pulanić,et al.  Thrombocytopenia and hemostatic disorders in chronic graft versus host disease , 2009, Bone Marrow Transplantation.

[8]  R. Komorowski,et al.  Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. , 2007, Blood.

[9]  B. Bain,et al.  Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres , 2007, British journal of haematology.

[10]  R. Yamazaki,et al.  Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover , 2006, Bone Marrow Transplantation.

[11]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  J. Armitage,et al.  Prognostic factors of chronic graft‐versus‐host disease after allogeneic blood stem‐cell transplantation , 2005, American journal of hematology.

[13]  J. Lynch,et al.  Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. , 2003, Blood.

[14]  H. Ito.  Anti-interleukin-6 therapy for Crohn's disease. , 2003, Current pharmaceutical design.

[15]  H. Tilg,et al.  Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. , 2001, Blood.

[16]  S. Piantadosi,et al.  Development of a prognostic model for grading chronic graft-versus-host disease. , 2001, Blood.

[17]  F. Frassoni,et al.  Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft‐versus‐host disease, donor type, cytomegalovirus infections and cell dose , 2001, British journal of haematology.

[18]  S. Honda,et al.  [Comparison of reticulated platelet count with plasma glycocalicin concentration as a marker of platelet turnover in patients with thrombocytopenic disorders]. , 2000, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[19]  N. Young,et al.  Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. , 1996, Blood.

[20]  Y. Niitsu,et al.  The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis , 1990 .

[21]  S. Lee,et al.  Feasibility of NIH consensus criteria for chronic graft-versus-host disease , 2009, Leukemia.

[22]  J. Walters,et al.  Performance Evaluation of the Sysmex XE-2100 Hematology Analyzer , 2000 .

[23]  J. Gastwirth.  Non-parametric Statistical Methods , 1990 .